When was Mesh Bio founded?

Mesh Bio was founded in 2018 and raised its 1st funding round 3 years after it was founded.

Where is Mesh Bio located?

Mesh Bio is headquartered in Singapore, Singapore.

Who is the current CEO of Mesh Bio?

Andrew Wu of Mesh Bio. They have also founded 1 company.

Which legal entities is Mesh Bio associated with?

Mesh Bio is associated with MESH BIO PTE. LTD..

How many employees does Mesh Bio have?

As of Jul 31, 2026, the latest employee count at Mesh Bio is 26.

Is Mesh Bio a funded company?

Mesh Bio is a funded company, having raised a total of $6.5M across 2 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Mar 10, 2021.

When was the latest funding round of Mesh Bio?

Mesh Bio's latest funding was a $***** Series A round on Oct 12, 2023, with participation from 3 investors.

What is the annual revenue of Mesh Bio?

Annual revenue of Mesh Bio is less than SGD 1M as on Dec 31, 2022

Where does Mesh Bio rank among its competitors?

Mesh Bio ranks 15th amongst 282 active competitors, of which 72 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was ThoroughCare, which secured $2.25M in May, 2026.

Who are the top competitors of Mesh Bio?

Mesh Bio's top competitors include Wellframe, Closedloop Medicine and Memora Health. Among them, ThoroughCare secured the most recent funding round in May, 2026.

Mesh Bio - 2026 Company Profile, Team, Funding, Competitors & Financials

Company Details

Mesh Bio provides software for chronic disease management through predictive analytics. The software translates clinical data and numbers into actionable insights that help patients better manage their health, lifestyle, and disease risks. The software provides clinical decision support for healthcare professionals

Website: www.meshbio.com/
Email ID: *****@meshbio.com

Key Metrics

Founded Year

2018

Location

Singapore, Singapore

Stage

Series A

Total Funding

$6.5M in 2 rounds

Latest Funding Round

Series A, Oct 12, 2023, $*****

Investors

East Ventures & 18 more

Ranked

15^th among 282 active competitors

Annual Revenue

SGD 0 - 1M as on Dec 31, 2022

Employee Count

26 as on Jul 31, 2026

Similar Companies

Wellframe & 424 more

View Mesh Bio's full profile

Mesh Bio is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
MESH BIO PTE. LTD. CIN: 201820887D , Singapore, Active	Jun 19, 2018	SGD 0 - 1M (As on Dec 31, 2022)	-

Mesh Bio has raised a total funding of $6.5M over 2 rounds. Its first funding round was on Mar 10, 2021. Its latest funding round was a Series A round on Oct 12, 2023 for $*****. 3 investors participated in its latest round. Mesh Bio has 11 institutional investors and 8 angel investors.

Here is the list of recent funding rounds of Mesh Bio:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Oct 12, 2023	8156232	Series A	2996664	1295875	2632570	7639710
Mar 10, 2021	7190556	Seed	5495418	1656277	Elev8 & 1 more	Citrine Capital & 1 more

Access funding benchmarks and valuations. Sign up today!

View details of Mesh Bio's funding rounds and investors

The founders of Mesh Bio are Melvin Heng and Andrew Wu. Andrew Wu is the CEO of Mesh Bio.

Here are the details of Mesh Bio's key team members:

Melvin Heng: Co-Founder & Advisor of Mesh Bio. They serve on the board of 1 company.
Contact Info: 1 email address
Andrew Wu: Co-Founder & CEO of Mesh Bio. They serve on the board of 1 company.
Contact Info: 1 email address

Mesh Bio's Board of Directors

Mesh Bio's board has 6 active members. Andrew Wu and Arsen Batagov are part of team and Willson Cuaca, Aditya Mathur, Reuben Lai Yuen Tung and Anastasia Ling Yew Lin are independent board members.

Here is the list of Mesh Bio's board of directors:

Name	Type	Representing	Status	Duration
Andrew Wu	Team	-	Current	8y 1m
Arsen Batagov	Team	-	Current	7y 5m
nybbzhk	Team	-	Past	7y 1m
Willson Cuaca	Independent board member	-	Current	2y 1m
rxybsok	Independent board member	-	Current	3y 1m
ncvetes	Independent board member	-	Current	7y 8m
qpcnuxx	Independent board member	-	Past	4y 8m
wvroozc	Independent board member	-	Past	7y 1m

View details of Mesh Bio's Founder profiles and Board Members

Mesh Bio's employee count trend

Mesh Bio has 26 employees as of Jul 26. Here is Mesh Bio's employee count trend over the years:

Uncover Mesh Bio's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Mesh Bio include Wellframe, Closedloop Medicine and Memora Health. Here is the list of Top 10 competitors of Mesh Bio, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Wellframe 2011, Boston (United States), Acquired	Mobile and AI-based platform offering support to providers for better patient engagement	$45.1M	F-Prime Capital, Rock Health & 14 others	67/100
2nd	Closedloop Medicine 2017, Cambridge (United Kingdom), Series A	Developer of personalized medicine platforms combining drug therapy and digital care	$30M	Martlet Capital, Ananda Impact Ventures & 15 others	66/100
3rd	Memora Health 2015, Boston (United States), Acquired	Mobile platform for chronic disease management	$80.6M	General Catalyst, Transformation Capital ... & 22 others	63/100
4th	Rimidi Diabetes 2012, Coral Gables (United States), Acquired	Cloud-based platform for diabetes management	$12.8M	Cox Investment Group, Lilly & 12 others	63/100
5th	ChartSpan 2012, Greenville (United States), Series A	Mobile app for Patient health records	$37.2M	Cypress Growth Capital, BIP Capital & 7 others	63/100
6th	VitalTech 2002, Plano (United States), Acquired	Provider of a cloud-based platform for monitoring patient and employee health	$26.3M	Tech Mahindra, Concord Health Partners & 2 others	62/100
7th	Brook 2015, Series A	Provider of remote patient care blending clinical teams with artificial intelligence	$32M	UMass, Morningside & 1 others	61/100
8th	TimeDoc 2015, Chicago (United States), Series B	Provider of the chronic care management solution for healthcare professionals	$56.7M	Vocap Partners, Grand Ventures & 7 others	56/100
9th	Glytec 2005, United States, Series C	Cloud based platform for diabetes and insulin management	$56.3M	Savitr Capital, Hayfin & 1 others	56/100
10th	ThoroughCare 2013, Spartanburg (United States), Series A	Care coordination software and clinical guidance to optimize patient care management	$13.2M	Cypress Growth Capital, Empactful Capital ... & 3 others	55/100
15th	Mesh Bio 2018, Singapore (Singapore), Series A	Provider of chronic disease management software	$6.5M	SEEDS Capital, YL Ventures & 17 others	50/100